Review of cardiotoxic effects of biotherapy and molecular targeted therapy in treatment of neuroendocrine neoplasms with somatostatin analogues, tryptophan hydroxylase, mTOR and tyrosine kinase inhibitors found that biotherapy has a significantly lower incidence of adverse cardiac events and exacerbations of pre-existing conditions. The gene discussed is MTOR; the disease is neuroendocrine neoplasm.